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Abstract
Small-volume resuscitation of critically ill patients with hyperoncotic
albumin offers a number of theoretical advantages, such as
increasing intravascular volume in excess of the volume of fluid
administered and reducing interstitial edema. Whilst iso-oncotic
albumin has been shown to be equi-effective to isotonic saline for
the resuscitation of critically ill patients without associated trau-
matic brain injury, the efficacy of hyperoncotic albumin for
resuscitation has not been evaluated in large-scale randomized-
controlled trials. Overall, the evidence for resuscitation with hyper-
oncotic albumin is limited by studies of poor methodological quality
with heterogenous study populations and control regimens. There
is marginal qualitative evidence of improvements in surrogate out-
comes in disparate patient populations, but no evidence of any
survival benefit associated with resuscitation with hyperoncotic
albumin. Given the lack of evidence and clinical uncertainty about the
efficacy of hyperoncotic albumin, a large-scale randomized-
controlled trial is required to determine its role in the acute
resuscitation of hypovolemic or hypoalbuminemic critically ill patients.
Resuscitation of critically ill patients with hyperoncotic fluids
offers a number of theoretical advantages. These are
presented in the systemic review by Jacob and colleagues in
this issue of Critical Care [1]. Based on the principles
described by Starling in 1896 [2], intravenous administration
of hyperoncotic fluids under physiological conditions
produces transient hypervolemia that may be augmented by
intravasation of interstitial fluid into the vascular compartment.
This may result in increased effective intravascular volume
that exceeds the volume of administered fluid and may
reduce pathological interstitial edema. Under time-critical
conditions such as traumatic brain injury, burns or severe
sepsis, resuscitation with small volumes of hyperoncotic fluid
appear attractive, particularly in the pre-hospital setting where
prompt delivery of smaller volumes of resuscitation solutions
may be more effectively administered.
Hypertonic crystalloids, such as saline, have been advocated
for small-volume resuscitation, particularly in the pre-hospital
setting. However, a double-blind randomized-controlled trial
comparing rapid infusion of 250 ml of 7.5% hypertonic saline
to Ringer’s lactate to patients with severe traumatic brain
injury did not demonstrate a difference in mortality or six-
month neurological outcomes [3].
Of the hyperoncotic colloids, albumin has been used for
resuscitation since the 1940s, primarily for acute resuscitation
in hypovolemic patients, but also for ‘slow’ resuscitation in
hypoalbuminemic patients with liver disease undergoing
abdominal paracentesis. Despite limited evidence for the use
of hyperoncotic albumin in these contexts, unequivocal
evidence for the efficacy of iso-oncotic (4%) albumin for
resuscitation of patients in the intensive care unit now exists
following the publication of the Saline versus Albumin Fluid
Evaluation (SAFE) study [4]. This study was prompted by the
publication of a meta-analysis of 1,104 patients from 24
studies that concluded that the use of albumin was associated
with an overall excess mortality of 6% [5]. The SAFE study
was a 6,997-patient, double-blind, prospective, randomized-
controlled trial that demonstrated no difference in all-cause
28-day mortality between patients who received albumin or
saline for intravenous resuscitation in the intensive care unit. In
addition to providing evidence of safety for the use of 4%
albumin for resuscitation in a heterogenous population of
patients, the SAFE study also provided some insights into the
effects of albumin in two important patient populations.
An additional analysis of 460 patients with traumatic brain
injury from the SAFE study (the SAFE-TBI study) demon-
strated that resuscitation with albumin was associated with
significantly higher two-year mortality compared to saline
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(33.2% versus 20.4%, relative risk (RR) 1.63, 95% confi-
dence intervals (CI) 1.17 to 2.26, p = 0.003) [6]. These data
provide compelling evidence for the selection of fluids or
resuscitation of patients with traumatic brain injury and
suggest that iso-oncotic albumin and, by inference,
hyperoncotic albumin, be avoided in these patients as it is
unlikely that such a study would be repeated.
Secondly, in 1,218 patients presenting with sepsis at base-
line, resuscitation with albumin was associated with a relative
risk of death of 0.87 (95% CI 0.74 to 1.02) compared to
saline, suggesting a potentially beneficial effect in sepsis that
requires further study.
However, extrapolation of the results of the SAFE study to
acute and ‘slow’ resuscitation with hyperoncotic colloids
requires caution. In this regard, the systematic review about
the efficacy of small-volume resuscitation with hyperoncotic
albumin solutions by Jacob and colleagues [1] is timely.
This review identified 25 randomized-controlled trials with a
total of 1,485 patients and is remarkably similar to the 1998
Cochrane Injuries Group Albumin Reviewers meta-analysis in
terms of evaluable studies, patient numbers and variability of
patient populations [5]. In contrast, Jacob and colleagues
used a qualitative summary of surrogate outcome measures
to determine the effects of hyperoncotic albumin on clinically
relevant endpoints such as morbidity, organ function, length
of stay and cost. A secondary quantitative meta-analysis on
the effects on survival was also performed on studies where
deaths were recorded on an intention-to-treat basis.
Overall, the quality of studies analyzed was poor, with a
median number of patients per trial of 30 (interquartile range
(IQR) 18 to 58) and only 3 of the 25 studies were conducted
under blinded conditions. A range of control regimens were
identified, the most common being comparisons with hydroxy-
ethyl starch in nine trials. Similarly, there was a range of
clinical conditions where hyperoncotic albumin was studied,
the most common of which was sepsis (328 patients from 7
trials, 6 of which were from one investigator), liver disease
(272 patients from 3 trials), neonates (81 patients from 3
trials) and one study of 18 patients with traumatic brain injury.
Despite these limitations, Jacob and colleagues conclude
that on the basis of qualitative analyses of a range of
surrogate outcome measures, the randomized-controlled
trials included in the analysis suggest limited evidence of
clinical benefit, such as reduction in morbidity in high-risk
neonates and brain injury, avoidance of major organ edema in
surgery and high-risk neonates, and preservation of renal
function in surgery and liver disease. With respect to survival
data, pooled data of 1,287 patients from 20 evaluable trials,
for which the median duration of follow-up was 5 days (IQR 5
to 13 days), demonstrated no difference between hyper-
oncotic albumin and ‘control’ (RR 0.95, 95% CI 0.78 to
1.17). Furthermore, survival data from the patients with sepsis
were opposite to the trend observed in patients with sepsis in
the SAFE study.
The strength of the conclusions from the qualitative analysis
of the included trials requires great caution given the
methodological limitations and heterogeneity of trials. The use
of outcomes subject to ascertainment bias, particularly in
unblinded studies or non-blinded outcome adjudication and
the use of surrogate outcome measure significantly question
the validity of these conclusions [7].
Accordingly, clinicians should not change practice on the
basis of this systematic review. Furthermore, the overall lack
of improved efficacy between hyperoncotic albumin and
control regimens demonstrated in the quantitative meta-
analysis tends to affirm the view of a revised Cochrane meta-
analysis that concluded that the use of colloid solutions for
acute resuscitation of hypovolemic patients outside the
context of randomized-controlled trials is difficult to justify [8].
This systematic review provides a useful summary of the
limited published evidence for the use of hyperoncotic
albumin for small-volume resuscitation. Clinical uncertainty
about the efficacy of its use remains, apart from patients with
traumatic brain injury where, on the basis of the SAFE-TBI
study, use of albumin for resuscitation is contraindicated [6].
The imperative following this systematic review is to design and
conduct a large-scale, double-blind, randomized-controlled trial
to address the efficacy and cost-effectiveness of small-volume
hyperoncotic albumin resuscitation in critically ill patients.
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